Dan L Duncan Comprehensive Cancer Center

Running trials

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  NCT07012044· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

  NCT06894979· Phase 1· Children's Oncology Group· Source

• Recruiting

  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Children's Oncology Group· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

  NCT06513962· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

  NCT06247787· Phase 1· Children's Oncology Group· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

  NCT06410209· Phase 2· Children's Oncology Group· Source

• Recruiting

  QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

  NCT06551116· Abramson Cancer Center at Penn Medicine· Source

• Recruiting

  Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  NCT05554393· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

  NCT05711667· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

  NCT06064097· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  NCT06203600· Phase 2/3· National Cancer Institute (NCI)· Source

• Recruiting

  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  NCT05564390· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

  NCT05761171· Phase 2· Children's Oncology Group· Source

• Recruiting

  A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

  NCT05702645· Children's Oncology Group· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

• Recruiting

  Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  NCT05561387· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

  NCT05146739· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  NCT05890352· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  NCT05929768· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

  NCT05602194· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

  NCT05705531· Children's Oncology Group· Source

• Recruiting

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· Phase 3· NRG Oncology· Source

• Recruiting

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  NCT05675410· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

  NCT05020860· Phase 2· Baylor Breast Care Center· Source

• Active, not recruiting

  Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

  NCT05457556· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Intravesical BCG vs GEMDOCE in NMIBC

  NCT05538663· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

  NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

  NCT05286801· Phase 1/2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Vincristine Pharmacokinetics in Infants

  NCT05359237· Children's Oncology Group· Source

• Recruiting

  A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

  NCT05504291· Phase 2· Children's Oncology Group· Source

• Recruiting

  Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  NCT05304585· Phase 3· Children's Oncology Group· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· NRG Oncology· Source

• Recruiting

  Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

  NCT05058651· Phase 2/3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  NCT05099003· Phase 1/2· National Cancer Institute (NCI)· Source

• Recruiting

  The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  NCT04726241· Phase 1/2· PedAL BCU, LLC· Source

• Recruiting

  Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  NCT05235165· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

  NCT05095376· Phase 3· NRG Oncology· Source

Showing 50 of 150.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers34 recruiting
• Acute myeloid leukaemia8 recruiting
• Acute lymphoblastic leukaemia7 recruiting
• Kidney cancer6 recruiting
• Ovarian cancer5 recruiting
• Sarcoma5 recruiting
• Down syndrome3 recruiting
• Myelodysplastic syndromes3 recruiting
• Neuroblastoma3 recruiting
• Pancreatic cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Bladder cancer2 recruiting
• Colorectal cancer2 recruiting
• Lung cancer2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Neuroendocrine tumours2 recruiting
• Prostate cancer2 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Cytomegalovirus infection1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Terminated

  Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

  NCT04751383· Phase 1· National Cancer Institute (NCI)· Source

• Terminated

  Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

  NCT04158141· Phase 3· NRG Oncology· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

  NCT03813147· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

  NCT03320330· Phase 1/2· Children's Oncology Group· Source

• Completed

  Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

  NCT03323034· Phase 1· Children's Oncology Group· Source

• Completed

  Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450· Children's Oncology Group· Source

• Completed

  Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  NCT03223753· Phase 3· Children's Oncology Group· Source

• Completed

  Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213691· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

  NCT03033576· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

  NCT03233204· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

  NCT02975882· Phase 1· Children's Oncology Group· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

  NCT02844816· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

  NCT02717507· Phase 2· Children's Oncology Group· Source

• Completed

  Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

  NCT02470091· Phase 2· Children's Oncology Group· Source

• Completed

  Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

  NCT02323880· Phase 1· Children's Oncology Group· Source

• Terminated

  Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

  NCT02408861· Phase 1· National Cancer Institute (NCI)· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

  NCT01979536· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

  NCT01798004· Phase 1· Children's Oncology Group· Source

• Completed

  S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

  NCT01809691· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

  NCT01553149· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666· Phase 2· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

  NCT01503632· Phase 3· Children's Oncology Group· Source

• Completed

  S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

  NCT01224665· SWOG Cancer Research Network· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

  NCT01236560· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Children's Oncology Group· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Children's Oncology Group· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Children's Oncology Group· Source

• Completed

  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

  NCT00653068· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

  NCT00336024· Phase 3· Children's Oncology Group· Source

• Completed

  Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

  NCT00392327· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Children's Oncology Group· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Children's Oncology Group· Source

Showing 50 of 57.

Conditions

Diseases this institution publishes on or runs trials for.

• Triple-negative breast cancer20 works · 5 trials